ORTEXORTEX News
Tracking CHD? Get live short interest, options flow, and signals on ORTEX.Sign up free →
CH
Earnings PreviewCHD

CHD Options Flash the Most Bullish Signal in a Year Before Thursday's Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 27 Oct 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Church & Dwight reports Q3 earnings on Thursday with one data point that stands out well above anything else in the setup: options traders have taken their most bullish position on the stock in at least 12 months. The put/call ratio closed Monday at 0.17, more than three standard deviations below its 20-day average of 0.37 and the lowest reading in the past year. That kind of skew toward calls rarely happens by accident ahead of a scheduled catalyst.

The price action reinforces the mood. CHD closed at $105.38, up 9.3% over the past month and 1.2% on the week, outpacing a peer median of roughly 0.7% (Colgate fell 0.3% on the week, Clorox gained 1.4%, Kimberly-Clark 4.0%). The borrow market does nothing to complicate that picture: availability is extremely loose at 2,116%, meaning there are more than 21 shares available to lend for every one already borrowed, and borrowing costs are minimal at 0.45%. Short interest at 5.1% of the free float has drifted roughly flat over the week, with no sign of fresh conviction in either direction from the short side.

The debate going into the print is not really about whether the business is working. The bull case rests on volume-led organic growth of 5.3% and distribution gains running 11% above peers, with brands like Arm & Hammer and Therabreath showing pricing resilience and the Touchland integration providing incremental runway. The bear case is more structural: roughly 80% of sales are US-sourced, Walmart alone accounts for more than 20% of revenue, and management flagged an incremental $25-30 million of cost inflation from oil-linked inputs this year. Bears also point to flat first-half EPS growth and softer international organic sales guidance of around 7%. Analyst opinion skews cautious overall, with Barclays maintaining an Underweight rating and trimming its target to $83 earlier this month, while Wells Fargo lowered its Overweight target to $105, now effectively in line with the current price. The broader analyst community is clustered around Neutral.

The last two quarterly prints both produced positive reactions: shares rose 2.4% on the day after Q2 results in July and added a further 5.7% over the five sessions that followed, with the Q1 print adding 1.2% on the day and 4.4% over the week. That recent pattern of modest beats and follow-through gains helps explain some of the call-skew in the options market. Neuberger Berman was a notable buyer in the most recent institutional reporting period, adding 1.3 million shares, while the big passive holders, BlackRock at 9.5% and two Vanguard entities together near 12.6%, have been slowly adding. Insider activity over the past 90 days is a net negative in share terms, but the transactions are predominantly option exercises followed by same-day sales rather than discretionary selling, reducing their signalling value.

Thursday's print will test whether the volume-led organic growth story can hold at a mid-20s price-to-earnings multiple while cost headwinds from oil-linked inputs widen, and whether any guidance commentary on the Walmart concentration and international softness shifts the calculus for a market that has already re-rated the stock sharply higher this autumn.

Stocks in this article

See the live data behind this article on ORTEX.

Open CHD on ORTEX →

How this article was generated

Generated
27 Oct 2026, 04:06
Data as of
27 Oct 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.